Drug Analysis: Injectafer

Drug Analysis: Injectafer

  • January 2018 •
  • 14 pages •
  • Report ID: 5336410 •
  • Format: PDF
Drug Overview
Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD). It is administered intravenously and is dissociated into iron and sucrose once in circulation.

The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell. Iron maintenance therapies like Injectafer have achieved widespread use by improving both the safety and cost-efficiency associated with treating anemia in CKD, reducing the doses of erythropoiesis-stimulating agents required to correct and maintain hemoglobin levels.